The DosR regulon of M. tuberculosis and antibacterial tolerance
- PMID: 19577518
- PMCID: PMC2718728
- DOI: 10.1016/j.tube.2009.06.001
The DosR regulon of M. tuberculosis and antibacterial tolerance
Abstract
Adaptation of Mycobacterium tuberculosis to an anaerobic dormant state that is tolerant to several antibacterials is mediated largely by a set of highly expressed genes controlled by DosR. A DosR mutant was constructed to investigate whether the DosR regulon is involved in antibacterial tolerance. We demonstrate that induction of the regulon is not required for drug tolerance either in vivo during a mouse infection or in vitro during anaerobic dormancy. Thus, drug tolerance observed in these models is due to other mechanisms such as the bacilli simply being in a non-replicating or low metabolic state. Our data also demonstrate that the DosR regulon is not essential for virulence during chronic murine infection. However, decreased lung pathology was observed in the DosR mutant. We also show that the DosR regulon genes are more highly conserved in environmental mycobacteria, than in pathogenic mycobacteria lacking a latent phase or environmental reservoir. It is possible that the DosR regulon could contribute to drug tolerance in human infections; however, it is not the only mechanism and not the primary mechanism for tolerance during a mouse infection. These data suggest that the regulon evolved not for pathogenesis or drug tolerance but for adaptation to anaerobic conditions in the environment and has been adapted by M. tuberculosis for survival during latent infection.
Figures
Similar articles
-
The Mycobacterium tuberculosis DosR regulon assists in metabolic homeostasis and enables rapid recovery from nonrespiring dormancy.J Bacteriol. 2010 Mar;192(6):1662-70. doi: 10.1128/JB.00926-09. Epub 2009 Dec 18. J Bacteriol. 2010. PMID: 20023019 Free PMC article.
-
Anaerobic Mycobacterium tuberculosis Cell Death Stems from Intracellular Acidification Mitigated by the DosR Regulon.J Bacteriol. 2017 Oct 31;199(23):e00320-17. doi: 10.1128/JB.00320-17. Print 2017 Dec 1. J Bacteriol. 2017. PMID: 28874407 Free PMC article.
-
Unique roles of DosT and DosS in DosR regulon induction and Mycobacterium tuberculosis dormancy.Infect Immun. 2009 Aug;77(8):3258-63. doi: 10.1128/IAI.01449-08. Epub 2009 Jun 1. Infect Immun. 2009. PMID: 19487478 Free PMC article.
-
Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis.Vaccine. 2014 Feb 3;32(6):712-6. doi: 10.1016/j.vaccine.2013.11.065. Epub 2013 Dec 2. Vaccine. 2014. PMID: 24300592 Review.
-
How Mycobacterium tuberculosis goes to sleep: the dormancy survival regulator DosR a decade later.Future Microbiol. 2012 Apr;7(4):513-8. doi: 10.2217/fmb.12.14. Future Microbiol. 2012. PMID: 22439727 Review.
Cited by
-
The granuloma in tuberculosis: dynamics of a host-pathogen collusion.Front Immunol. 2013 Jan 7;3:411. doi: 10.3389/fimmu.2012.00411. eCollection 2012. Front Immunol. 2013. PMID: 23308075 Free PMC article.
-
Adaptation to environmental stimuli within the host: two-component signal transduction systems of Mycobacterium tuberculosis.Microbiol Mol Biol Rev. 2011 Dec;75(4):566-82. doi: 10.1128/MMBR.05004-11. Microbiol Mol Biol Rev. 2011. PMID: 22126994 Free PMC article. Review.
-
Adaptation of Mycobacterium tuberculosis to Impaired Host Immunity in HIV-Infected Patients.J Infect Dis. 2016 Oct 15;214(8):1205-11. doi: 10.1093/infdis/jiw364. Epub 2016 Aug 17. J Infect Dis. 2016. PMID: 27534685 Free PMC article.
-
Mycobacterial Dormancy Systems and Host Responses in Tuberculosis.Front Immunol. 2017 Feb 15;8:84. doi: 10.3389/fimmu.2017.00084. eCollection 2017. Front Immunol. 2017. PMID: 28261197 Free PMC article. Review.
-
Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.Antimicrob Agents Chemother. 2011 Mar;55(3):1237-47. doi: 10.1128/AAC.00595-10. Epub 2010 Dec 6. Antimicrob Agents Chemother. 2011. PMID: 21135176 Free PMC article.
References
-
- Dye C, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Jama. 1999. pp. 677–686. - PubMed
-
- Wallis RS, Palaci M, Eisenach K. Persistence, not resistance, is the cause of loss of isoniazid effect. J Infect Dis. 2007;195(12):1870–1871. author reply 1872-3. - PubMed
-
- Mitchison DA, et al. Isoniazid activity is terminated by bacterial persistence. J Infect Dis. 2007;195(12):1871–1872. author reply 1872-3. - PubMed
-
- Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004;84(1–2):29–44. - PubMed
MeSH terms
Substances
Grants and funding
- R01 AI061505/AI/NIAID NIH HHS/United States
- R15 AI068706-01A1/AI/NIAID NIH HHS/United States
- R01 AI061505-05/AI/NIAID NIH HHS/United States
- R15 AI068706/AI/NIAID NIH HHS/United States
- R01 AI061505-04/AI/NIAID NIH HHS/United States
- T32 AI052066/AI/NIAID NIH HHS/United States
- R01 AI061505-03/AI/NIAID NIH HHS/United States
- R01 AI061505-01A1/AI/NIAID NIH HHS/United States
- R01 AI061505-02/AI/NIAID NIH HHS/United States
- R01 AI044826-05/AI/NIAID NIH HHS/United States
- R01 AI044826/AI/NIAID NIH HHS/United States
- T32 AI052066-06/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical